# Rhamnus cathartica

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/rhamnus-cathartica
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** European
**Also Known As:** Common buckthorn, European buckthorn, Purging buckthorn, Common waythorn, Buckthorn, Waythorn, Hartshorn, Ram's thorn

## Overview

Rhamnus cathartica, common buckthorn, contains anthraquinone glycosides such as emodin and frangulin that drive its laxative and [antimicrobial](/ingredients/condition/immune-support) properties. These compounds stimulate colonic motility and disrupt bacterial quorum sensing, reducing virulence factor expression in pathogenic bacteria.

## Health Benefits

• Antibacterial activity: Demonstrated 11.3-16mm inhibition zones against Gram-positive and Gram-negative bacteria (preliminary in vitro evidence)
• Quorum sensing inhibition: Reduced Pseudomonas aeruginosa virulence factors by 61% for elastase and biofilm formation (preliminary in vitro evidence)
• Potential anti-cancer effects: Tested on AGS and MKN45 gastric cancer cell lines (preliminary in vitro evidence, no quantitative data)
• Traditional laxative effects: Recognized as a cathartic plant (traditional use only)
• [Antimicrobial](/ingredients/condition/immune-support) biofilm reduction: 61% reduction in bacterial biofilm formation (preliminary in vitro evidence)

## Mechanism of Action

The anthraquinone glycosides in Rhamnus cathartica, particularly emodin and frangulin B, are hydrolyzed by colonic bacteria into active aglycones that stimulate Auerbach's plexus and increase intestinal peristalsis while inhibiting Na+/K+-ATPase in colonocytes. Emodin also inhibits bacterial LasR and RhlR quorum sensing receptors in Pseudomonas aeruginosa, suppressing elastase (LasB) production and biofilm matrix synthesis by approximately 61%. Additionally, phenolic constituents disrupt bacterial membrane integrity, explaining the observed 11.3–16 mm inhibition zones against both Gram-positive and Gram-negative organisms in agar diffusion assays.

## Clinical Summary

Evidence for Rhamnus cathartica is predominantly preclinical; in vitro studies demonstrate 11.3–16 mm inhibition zones against Gram-positive and Gram-negative bacteria and a 61% reduction in Pseudomonas aeruginosa elastase activity and biofilm formation. The German Commission E has approved buckthorn bark and berry preparations for short-term use in constipation, based largely on its anthraquinone content and mechanistic data rather than large randomized controlled trials. No adequately powered human clinical trials specifically isolating Rhamnus cathartica extract have been published, limiting conclusions about efficacy and optimal dosing in human populations. Overall, evidence quality is rated preliminary to low, and extrapolation from related anthraquinone-containing species such as Rhamnus frangula or Cassia senna is required to contextualize its therapeutic profile.

## Nutritional Profile

Rhamnus cathartica (Common Buckthorn) is not consumed as a food source and lacks a conventional nutritional profile; it is primarily recognized for its phytochemical/bioactive compound content rather than macro- or micronutrient value. Key bioactive compounds include: • Anthraquinone glycosides (primary purgative compounds): emodin (approximately 0.1–0.8% dry weight in bark and fruit), chrysophanol, and frangulin A & B — these are the principal cathartic agents responsible for the plant's historical use as a laxative. • Flavonoids: kaempferol, quercetin, and rhamnetin glycosides (estimated 0.5–2.0% in leaves and fruit); rhamnocitrin and isorhamnetin also reported in small quantities. • Anthranoids: glucofrangulin A and B present in bark at approximately 3–6% total anthranoid content (calculated as glucofrangulin A). • Tannins: condensed and hydrolyzable tannins present at approximately 2–5% in bark. • Organic acids: malic acid and citric acid detected in fruit pulp. • Fruit pigments: rhamnetin-based compounds contributing yellow-green coloration; historically used as dye. • Vitamin C: trace amounts reported in fresh fruit (not quantified with precision, likely <10 mg/100g). • Minerals: minor amounts of potassium, calcium, and magnesium detected in leaf and bark tissue (no standardized quantification for dietary purposes). • Fiber: fruit contains pectin and cellulose (fruit is small, ~6–8mm diameter, predominantly seed by mass). • Sugars: fruit pulp contains small amounts of glucose and fructose. • Emodin bioavailability note: emodin is poorly absorbed orally (bioavailability estimated at <5% in animal models) and undergoes extensive first-pass glucuronidation and sulfation in the liver and intestinal wall; anthraquinone glycosides require hydrolysis by colonic bacteria to release active aglycones, meaning cathartic effects are largely colon-specific. • Toxicity note: the fruit and bark are considered mildly toxic; ingestion of fresh berries causes severe gastrointestinal cramping, nausea, and diarrhea, and the plant is classified as poisonous in most pharmacopoeias — it is NOT suitable for nutritional consumption. All values are approximate and derived from phytochemical analyses rather than food composition databases.

## Dosage & Preparation

No clinically studied dosage ranges for human use are available. Preclinical studies used undefined methanol extracts for in vitro assays or 5-25% plant material in rodent diets for toxicity testing. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Rhamnus cathartica is contraindicated in individuals with intestinal obstruction, [inflammatory](/ingredients/condition/inflammation) bowel disease, appendicitis, or abdominal pain of unknown origin, as stimulant laxative action can worsen these conditions. Chronic use beyond 1–2 weeks risks pseudomelanosis coli, hypokalemia, and electrolyte imbalances that may potentiate cardiac glycoside toxicity, particularly with digoxin co-administration. Potassium depletion caused by prolonged anthraquinone use can enhance the effects of antiarrhythmic drugs and corticosteroids, necessitating caution. Rhamnus cathartica is not recommended during pregnancy or lactation due to potential uterotonic effects of emodin and lack of human safety data.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses on Rhamnus cathartica were identified. Available research is limited to preclinical studies, including one in vitro antibacterial study (PMID: 39743783) showing quorum sensing inhibition via kaempferol docking to LasR receptor, and another investigating anti-cancer effects on gastric cancer cell lines.

## Historical & Cultural Context

Rhamnus cathartica is recognized as a cathartic (purgative) plant with traditional laxative effects. The plant has been investigated for toxicity after suspected links to neurologic disease in horses, though specific historical medicinal systems or duration of use are not documented in available sources.

## Synergistic Combinations

Senna, Cascara sagrada, Aloe vera, Psyllium husk, Magnesium citrate

## Frequently Asked Questions

### What are the active compounds in Rhamnus cathartica?

The primary bioactive compounds are anthraquinone glycosides, specifically frangulin A and B, emodin, and rhamnoxanthin. Upon reaching the colon, gut bacteria cleave the glycoside bonds to release free aglycones, which are the pharmacologically active forms responsible for laxative and antimicrobial effects.

### Is Rhamnus cathartica approved for any medical use?

The German Commission E has approved preparations derived from buckthorn bark for short-term relief of constipation, specifying use should not exceed 1–2 weeks without medical supervision. This approval is based on its anthraquinone content and established laxative mechanism rather than large-scale randomized clinical trials.

### How does Rhamnus cathartica fight bacterial infections?

In vitro studies show that Rhamnus cathartica extracts produce inhibition zones of 11.3–16 mm against both Gram-positive and Gram-negative bacteria, likely through phenolic-mediated membrane disruption. Separately, emodin inhibits Pseudomonas aeruginosa quorum sensing receptors LasR and RhlR, reducing elastase production and biofilm formation by approximately 61%, though these findings have not yet been confirmed in human clinical trials.

### What are the side effects of taking Rhamnus cathartica?

Common side effects include cramping, diarrhea, and nausea due to stimulant laxative action on the colon. Long-term use can lead to electrolyte imbalances, particularly hypokalemia, and may cause pseudomelanosis coli, a reversible darkening of the colon lining; dependency with reduced intestinal motility is also a risk with prolonged use.

### Can Rhamnus cathartica interact with medications?

Yes, hypokalemia induced by chronic use can potentiate the toxicity of cardiac glycosides such as digoxin and amplify the effects of antiarrhythmic drugs and corticosteroids. It may also reduce the absorption of orally administered medications by accelerating gastrointestinal transit, and should be used with caution alongside diuretics that independently lower potassium levels.

### What does the research evidence show about Rhamnus cathartica's effectiveness?

Current evidence for Rhamnus cathartica is primarily preliminary and limited to in vitro (laboratory) studies, with demonstrated antibacterial activity showing inhibition zones of 11.3-16mm against both Gram-positive and Gram-negative bacteria. Research has also shown promising quorum sensing inhibition, reducing Pseudomonas aeruginosa virulence factors by 61%, though human clinical trials are lacking. Any potential anti-cancer properties observed in gastric cancer cell lines (AGS and MKN45) remain in early experimental stages and have not been validated in human studies.

### Who should avoid Rhamnus cathartica, and are there specific populations at higher risk?

Pregnant women and nursing mothers should exercise caution with Rhamnus cathartica due to limited safety data in these populations, as traditional use indicates potential effects on the digestive system. Children may be at increased risk for adverse effects given their smaller body mass and developing organ systems, making professional guidance essential. Individuals with inflammatory bowel conditions, severe gastrointestinal disorders, or those taking anticoagulants should avoid use without consulting a healthcare provider, as the plant's traditional laxative properties and bioactive compounds may pose additional risks.

### How do different forms or preparations of Rhamnus cathartica affect its bioavailability?

The bioavailability of Rhamnus cathartica varies significantly depending on whether it is used as a whole plant extract, standardized extract, or isolated anthraquinone compounds, though specific comparative data is limited. Traditional preparations such as decoctions or tinctures may extract different active compounds compared to modern standardized extracts, potentially affecting both efficacy and safety profiles. Processing methods and the plant part used (bark, fruit, or leaves) influence the concentration of active constituents, with bark typically containing higher levels of therapeutic compounds than other plant parts.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*